NORTH CHICAGO, Ill. and NEW YORK, May 13, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Gilgamesh Pharmaceuticals today announced a collaboration and option-to-license agreement to develop next-generation therapies for psychiatric disorders. This collaboration will leverage AbbVie's expertise in psychiatry and Gilgamesh's innovative research platform to discover novel neuroplastogens..

伊利诺伊州北芝加哥和纽约，2024年5月13日/PRNewswire/--AbbVie（纽约证券交易所：ABBV）和Gilgamesh Pharmaceuticals今天宣布了一项合作和许可协议选择，以开发下一代治疗精神疾病的疗法。这项合作将利用AbbVie在精神病学方面的专业知识和Gilgamesh的创新研究平台来发现新型神经塑化剂。。

Classic psychedelic compounds provide novel mechanisms to address mental health disorders, and some have shown promising clinical efficacy where other treatments have been ineffective. However, these first-generation compounds may induce profound psychoactive effects, such as hallucinations, necessitating in-office administration and concomitant supportive care..

经典的迷幻化合物为解决心理健康障碍提供了新的机制，有些化合物在其他治疗无效的情况下显示出有希望的临床疗效。然而，这些第一代化合物可能会引起深刻的精神作用，例如幻觉，需要办公室管理和伴随的支持治疗。。

Next-generation versions known as neuroplastogens target mechanisms that have shown potential to provide significant clinical benefits and are designed to minimize the challenging effects seen with first-generation compounds. These new compounds hold substantial promise for treating a variety of psychiatric conditions, including mood and anxiety disorders.

下一代版本称为神经塑化剂，其靶向机制已显示出提供显着临床益处的潜力，并且旨在最大程度地减少第一代化合物所见的挑战性作用。这些新化合物有望治疗多种精神疾病，包括情绪和焦虑症。

Gilgamesh has leveraged an innovative research platform to successfully identify lead compounds in this novel class of therapeutics..

吉尔伽美什利用一个创新的研究平台成功地鉴定了这类新型疗法中的先导化合物。。

'Significant unmet need remains for people living with psychiatric disorders and we know that to innovate in this field, we need to pursue novel technologies and approaches,' said Jonathon Sedgwick, Ph.D., senior vice president and global head of discovery research at AbbVie. 'We look forward to working with Gilgamesh's world-class team to advance the development of novel neuroplastogens and pave the way for additional treatment approaches in psychiatry.'.

AbbVie高级副总裁兼发现研究全球负责人乔纳森·塞奇威克（JonathonSedgwick）博士说：“精神疾病患者的需求仍未得到满足，我们知道要在这一领域进行创新，我们需要寻求新的技术和方法。”我们期待着与Gilgamesh的世界级团队合作，推动新型神经塑化剂的开发，并为精神病学的其他治疗方法铺平道路。”。

'We are thrilled to partner with AbbVie, a global pharmaceutical company focused on innovation in psychiatric care, to address the pressing challenges in mental health treatment,' said Jonathan Sporn, M.D., chief executive officer at Gilgamesh Pharmaceuticals. 'Our collaboration will pioneer research of a new generation of therapies that hold great potential for improving patient outcomes.'.

Gilgamesh Pharmaceuticals首席执行官乔纳森·斯普林（JonathanSporn）医学博士说，我们很高兴与专注于精神病治疗创新的全球制药公司AbbVie合作，以应对心理健康治疗方面的紧迫挑战我们的合作将开创新一代疗法的研究，这些疗法在改善患者预后方面具有巨大潜力。”。

Under terms of the agreement, AbbVie and Gilgamesh have agreed to research and develop a portfolio of next-generation therapeutics for psychiatric disorders. Upon exercise of the option, AbbVie will lead development and commercialization activities. Gilgamesh will receive an upfront payment of $65 million from AbbVie and is eligible to receive up to $1.95 billion in aggregate option fees and milestones, as well as tiered royalties from mid-single to low-double digits on net sales..

根据协议条款，AbbVie和Gilgamesh同意研究和开发下一代精神疾病治疗药物组合。行使期权后，AbbVie将领导开发和商业化活动。Gilgamesh将从AbbVie获得6500万美元的预付款，并有资格获得高达19.5亿美元的总期权费和里程碑，以及从净销售额的中单位数到低两位数的分层版税。。

About AbbVie

关于AbbVie

AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio.

AbbVie的使命是发现并提供创新药物和解决方案，以解决当今严重的健康问题，并应对未来的医疗挑战。我们致力于在几个关键治疗领域（免疫学、肿瘤学、神经科学和眼部护理）以及Allergan美学产品组合中的产品和服务，对人们的生活产生重大影响。

For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X (formerly Twitter), and YouTube..

有关AbbVie的更多信息，请访问www.AbbVie.com。在LinkedIn、Facebook、Instagram、X（以前的Twitter）和YouTube上关注@AbbVie。。

About Gilgamesh Pharmaceuticals

关于Gilgamesh Pharmaceuticals

Gilgamesh Pharmaceuticals is a clinical stage neuroscience biotech developing innovative, best-in-class new chemical entities (NCEs) that target the root causes of psychiatric diseases, moving away from symptom management towards rapid-acting and durable, disease modifying therapies. We do this by designing best-in-class NCEs acting through proven mechanisms, which are optimized for safety, efficacy, and patient access.

Gilgamesh Pharmaceuticals是一种临床阶段的神经科学生物技术，开发创新的，一流的新型化学实体（NCE），针对精神疾病的根本原因，从症状管理转向快速有效和持久的疾病缓解疗法。我们通过设计一流的NCE来实现这一目标，这些NCE通过经过验证的机制发挥作用，这些机制针对安全性，有效性和患者访问进行了优化。

Gilgamesh is advancing a diverse portfolio of programs, including two lead clinical programs, GM-1020 and GM-2505, which have both commenced Phase 2 studies in Major Depressive Disorder. Learn more about the company's therapeutic pipeline at https://www.gilgameshpharmaceutical.com/..

吉尔伽美什正在推进多种多样的项目组合，包括两个领先的临床项目GM-1020和GM-2505，这两个项目都已经开始了重性抑郁症的2期研究。了解有关该公司治疗渠道的更多信息，请访问https://www.gilgameshpharmaceutical.com/..